Oxaliplatin
Active ingredient: Oxaliplatin
In short: Oxaliplatin injection, in combination with infusional fluorouracil and leucovorin, is indicated for: adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor. treatment of advanced colorectal cancer.
What is Oxaliplatin used for?
Oxaliplatin injection, in combination with infusional fluorouracil and leucovorin, is indicated for:
adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor.
treatment of advanced colorectal cancer.
ā Boxed warning (FDA's strongest warning)
Serious and fatal hypersensitivity adverse reactions, including anaphylaxis, can occur
with oxaliplatin within minutes of administration and during any cycle. Oxaliplatin is contraindicated in patients with hypersensitivity reactions to oxaliplatin and other platinum-based drugs . Immediately and permanently discontinue oxaliplatin for hypersensitivity reactions and administer appropriate treatment for management of the hypersensitivity reaction .
Oxaliplatin dosage
Administer oxaliplatin injection in combination with fluorouracil and leucovorin every 2 weeks.
⢠For adjuvant treatment, continue treatment for up to 12 cycles or unacceptable toxicity. ⢠For advanced colorectal cancer, continue treatment until disease progression or unacceptable toxicity.
Day 1
Administer oxaliplatin injection 85 mg/m2 as an intravenous infusion over 120 minutes and leucovorin 200 mg/m2 as an intravenous infusion over 120 minutes at the same time in separate bags, followed by fluorouracil 400 mg/m2 as intravenous bolus over 2 to 4 minutes, followed by fluorouracil 600 mg/m2 as a 22-hour continuous infusion.
Day 2
Administer leucovorin 200 mg/m2 as an intravenous infusion over 120 minutes, followed by fluorouracil 400 mg/m2 as intravenous bolus over 2 to 4 minutes, followed by fluorouracil 600 mg/m2 as a 22-hour continuous infusion.
Refer to the prescribing information for fluorouracil and leucovorin for additional information.
Prolongation of infusion time for oxaliplatin injection from 2 hours to 6 hours may mitigate acute toxicities, such as non-life-threatening infusion-related reactions. Permanently discontinue oxaliplatin injection for any of the following:
⢠Hypersensitivity Reactions
⢠Posterior reversible encephalopathy syndrome (PRES)
⢠Confirmed interstitial lung disease or pulmonary fibrosis
⢠Rhabdomyolysis
Refer to the fluorouracil and leucovorin prescribing information for dosage modifications for adverse reactions.
Dosage Modifications for Adjuvant Treatment
Dosage modifications for adverse reactions for adjuvant treatment are presented in Table 1.
Table 1: Dosage Modifications for Adjuvant Treatment in Patients with Stage III Colon Cancer
Adverse Reactions | Severity | Oxaliplatin Injection Dosage Modifications
Peripheral Sensory Neuropathy | Persistent Grade 2 | Consider reducing oxaliplatin injection dose to 75 mg/m2.
Persistent Grade 3 | Consider discontinuing oxaliplatin injection.
Grade 4 | Discontinue oxaliplatin injection.
Myelosuppression . | Grade 4 neutropenia or febrile neutropenia | Delay the next dose until neutrophils greater than or equal to 1.5 Ć 109/L and platelets greater than or equal to 75 Ć 109/L. Reduce oxaliplatin injection dose to 75 mg/m2.
Grade 3 to 4 thrombocytopenia
Gastrointestinal Adverse Reactions | Grade 3 to 4 | After recovery, reduce oxaliplatin injection dose to 75 mg/m2 along with a dose reduction of fluorouracil to 300 mg/m2 as an intravenous bolus and 500 mg/m2 as a 22-hour continuous infusion.
Dosage Modifications for Advanced Colorectal Cancer
Dosage modifications for adverse reactions for advanced colorectal cancer are presented in Table 2. ā¦
How to take Oxaliplatin ā instructions & advice from the label
Hypersensitivity Reactions
Advise patients of the potential risk of hypersensitivity and that oxaliplatin injection is contraindicated in patients with a history of hypersensitivity reactions to oxaliplatin and other platinum-based drugs. Instruct patients to seek immediate medical attention for signs of severe hypersensitivity reaction such as chest tightness; shortness of breath; wheezing; dizziness or faintness; or swelling of the face, eyelids, or lips .
Peripheral Sensory Neuropathy
Advise patients of the risk of acute reversible or persistent-type neurosensory toxicity. Advise patients to avoid cold drinks, use of ice, and exposure of skin to cold temperature or cold objects .
Myelosuppression
Inform patients that oxaliplatin injection
can cause low blood cell counts and the need for frequent monitoring of blood cell counts. Advise patients to contact their healthcare provider immediately for bleeding, fever, particularly if associated with persistent diarrhea, or symptoms of infection develop . ā¦
Warnings & precautions
Do not take this medicine if: Oxaliplatin is contraindicated in patients with a history of a hypersensitivity reaction to oxaliplatin or other platinum-based drugs. Reactions have included anaphylaxis .
Serious and fatal hypersensitivity reactions, including anaphylaxis, can occur with oxaliplatin within minutes of administration and during any cycle. Grade 3 to 4 hypersensitivity reactions, including anaphylaxis, occurred in 2% to 3% of patients with colon cancer who received oxaliplatin. Hypersensitivity reactions, including rash, urticaria, erythema, pruritus, and rarely, bronchospasm and hypotension, were similar in nature and severity to those reported with other platinum-based drugs.
Oxaliplatin is contraindicated in patients with hypersensitivity reactions to platinum-based drugs . Immediately and permanently discontinue oxaliplatin for hypersensitivity reactions and administer appropriate treatment for management of hypersensitivity reactions.
Oxaliplatin can cause acute and delayed neuropathy. Reduce the dose or permanently discontinue oxaliplatin for persistent neurosensory reactions based on the severity of the adverse reaction .
Acute Neuropathy
Acute neuropathy typically presents as a reversible, primarily peripheral sensory neuropathy that occurs within hours or 2 days following a dose, resolves within 14 days, and frequently recurs with further dosing. The symptoms can be precipitated or exacerbated by exposure to cold temperature or cold objects and they usually present as transient paresthesia, dysesthesia and hypoesthesia in the hands, feet, perioral area, or throat. Jaw spasm, abnormal tongue sensation, dysarthria, eye pain, and a feeling of chest pressure have also been observed. The acute, reversible pattern of sensory neuropathy was observed in about 56% of patients who received oxaliplatin with fluorouracil/leucovorin. ā¦
Oxaliplatin side effects
The following clinically significant adverse reactions are described elsewhere in labeling:
Hypersensitivity Reactions
Peripheral Sensory Neuropathy
Severe Myelosuppression
Reversible Posterior Leukoencephalopathy Syndrome
Pulmonary Toxicity
Hepatotoxicity
QT Interval Prolongation and Ventricular Arrhythmias
Rhabdomyolysis
Hemorrhage
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
More than 1100 patients with stage II or III colon cancer and more than 4,000 patients with advanced colorectal cancer were treated in trials with oxaliplatin. The most common adverse reactions in patients with stage II or III colon cancer receiving adjuvant treatment were peripheral sensory neuropathy, neutropenia, thrombocytopenia, anemia, nausea, increase in transaminases and alkaline phosphatase, diarrhea, emesis, fatigue and stomatitis. The most common adverse reactions in previously untreated and treated patients with advanced colorectal cancer were peripheral sensory neuropathies, fatigue, neutropenia, nausea, emesis, and diarrhea.
Adjuvant Treatment
The safety of oxaliplatin in combination with fluorouracil (FU)/leucovorin (LV) was evaluated in patients with stage II or III colon cancer, who had undergone complete resection of the primary tumor in the adjuvant treatment trial . ā¦
Drug interactions
QT interval prolongation and ventricular arrhythmias can occur with oxaliplatin . Avoid coadministration of oxaliplatin with medicinal products with a known potential to prolong the QT interval.
Because platinum-containing species are eliminated primarily through the kidney, clearance of these products may be decreased by coadministration of potentially nephrotoxic compounds . Avoid coadministration of oxaliplatin with medicinal products known to cause nephrotoxicity.
Prolonged prothrombin time and INR occasionally associated with hemorrhage have been reported in patients who received oxaliplatin with fluorouracil/leucovorin while on anticoagulants . Increase frequency of monitoring in patients who are receiving oxaliplatin with fluorouracil/leucovorin and oral anticoagulants.
About this medicine
Oxaliplatin is a platinum-based drug with the molecular formula C8H14N2O4Pt and the chemical name of cis-[(1 R,2 R)-1,2-cyclohexanediamine-N,Nā²] [oxalato(2-)- O,Oā²] platinum. Oxaliplatin is an organoplatinum complex in which the platinum atom is complexed with 1,2- diaminocyclohexane (DACH) and with an oxalate ligand as a leaving group.
The molecular weight is 397.3. Oxaliplatin is slightly soluble in water at 6 mg/mL, very slightly soluble in methanol, and practically insoluble in ethanol and acetone.
Oxaliplatin injection, for intravenous use is supplied in vials containing 50 mg, 100 mg or 200 mg of oxaliplatin, USP as a sterile, preservative-free, aqueous solution at a concentration of 5 mg/mL. Water for Injection, USP is present as an inactive ingredient.
How it works: Oxaliplatin undergoes nonenzymatic conversion in physiologic solutions to active derivatives via displacement of the labile oxalate ligand. Several transient reactive species are formed, including monoaquo and diaquo DACH platinum, which covalently bind with macromolecules. ā¦
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID a6f89dc3-a594-4b5b-8728-272e20c1ecb5. Read the full official label on DailyMed.
Related medicines
Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate